Induction of epithelial-mesenchymal transition with O-glycosylated oncofetal fibronectin

FEBS Lett. 2012 Jun 21;586(13):1813-20. doi: 10.1016/j.febslet.2012.05.020. Epub 2012 May 26.

Abstract

Epithelial-mesenchymal transition (EMT) has been shown to play a key role in embryogenesis and cancer progression. We previously found that fibronectin (FN) carrying O-GalNAc at a specific site is selectively expressed in cancer and fetal cells/tissues, and termed oncofetal FN (onfFN). Here, we show that (i) a newly-established monoclonal antibody against FN lacking the O-GalNAc, termed normalFN (norFN), is useful for isolation of onfFN, (ii) onfFN, but not norFN, can induce EMT in human lung carcinoma cells, (iii) onfFN has a synergistic effect with transforming growth factor (TGF)β1 in EMT induction.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / metabolism
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Cell Line, Tumor
  • Epithelial-Mesenchymal Transition / immunology
  • Epithelial-Mesenchymal Transition / physiology*
  • Fibronectins / metabolism*
  • Glycated Proteins
  • Glycation End Products, Advanced
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Antibodies, Monoclonal
  • Fibronectins
  • Glycation End Products, Advanced
  • Transforming Growth Factor beta1
  • glycated fibronectin
  • Glycated Proteins
  • oncofetal fibronectin